VJHemOnc is committed to improving our service to you

ASCO 2020 | Update on CARTITUDE-1: CAR-T in RRMM

VJHemOnc is committed to improving our service to you

Jesús Berdeja

Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, gives an update on CARTITUDE-1 (NCT03548207), a phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy in relapsed/refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter